Neumora Therapeutics, Inc. Common Stock Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock

NMRA

Rank in Stocks #21554
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company... Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Share Price
$0.3339
Last synced: 2026-11-20
Market Cap
$62.74M
Change (1 day)
-3.78%
Change (1 year)
-85.67%
Country

Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this

Trade Neumora Therapeutics, Inc. Common Stock (NMRA)

Category

Healthcare
P/E ratio for Neumora Therapeutics, Inc. Common Stock (NMRA)
P/E ratio as of November 2026 TTM: -0.35
According to Neumora Therapeutics, Inc. Common Stock's latest financial reports and stock price, its current price-to-earnings ratio (TTM) is -0.35. At the end of 2025 the company had a P/E ratio of -1.23.
P/E ratio history for Neumora Therapeutics, Inc. Common Stock from 2019 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.35 -71.65%
2025 -1.23 -82.19%
2024 -6.93 -39.63%
2023 -11.48 -39.15%
2022 -18.86 81.29%
2021 -10.40 -58.17%
2020 -24.87 0.00%
2019 0.00 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
34.39 -9,963.32%
US
-31.59 8,960.54%
US
-25.99 7,352.05%
AU
25.67 -7,461.92%
BE
45.52 -13,153.57%
NL
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.

Questions about Neumora Therapeutics, Inc. Common Stock's P/E ratio

What is Neumora Therapeutics, Inc. Common Stock's P/E ratio?

Neumora Therapeutics, Inc. Common Stock's P/E ratio is -0.35, as of Nov 2026.

What was Neumora Therapeutics, Inc. Common Stock's P/E ratio in 2025?

In 2025, Neumora Therapeutics, Inc. Common Stock's P/E ratio was -1.23, compared with -6.93 in 2024.

How has Neumora Therapeutics, Inc. Common Stock's P/E ratio changed since 2020?

From 2020 to 2025, Neumora Therapeutics, Inc. Common Stock's P/E ratio was highest in 2025 (-1.23) and lowest in 2020 (-24.87).

How does Neumora Therapeutics, Inc. Common Stock's P/E ratio compare with similar companies?

Neumora Therapeutics, Inc. Common Stock's P/E ratio (-0.35) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with 45.52.